{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T11:20:19Z","timestamp":1785151219357,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["slas-technology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["SLAS Technology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.slast.2023.06.005","type":"journal-article","created":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T09:29:44Z","timestamp":1688290184000},"page":"369-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Capillary electrophoresis methods for determining the IVT mRNA critical quality attributes of size and purity"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5166-1789","authenticated-orcid":false,"given":"Denise A","family":"Warzak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7853-6563","authenticated-orcid":false,"given":"Whitney A","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8537-9404","authenticated-orcid":false,"given":"Kyle D","family":"Luttgeharm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.slast.2023.06.005_bib0001","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"key":"10.1016\/j.slast.2023.06.005_bib0002","unstructured":"U.S. Government Accountability Office Science & Tech Spotlight: COVID-19 Vaccine Development. 2021; Available from: https:\/\/www.gao.gov\/products\/gao-20-583sp."},{"issue":"10","key":"10.1016\/j.slast.2023.06.005_bib0003","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.slast.2023.06.005_bib0004","series-title":"Takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine","year":"2020"},{"key":"10.1016\/j.slast.2023.06.005_bib0005","series-title":"Statement from NIH and BARDA on the FDA emergency use authorization of the moderna COVID-19 vaccine","year":"2020"},{"key":"10.1016\/j.slast.2023.06.005_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111953","article-title":"Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2","volume":"142","author":"Granados-Riveron","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"10249","key":"10.1016\/j.slast.2023.06.005_bib0007","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.slast.2023.06.005_bib0008","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"issue":"10240","key":"10.1016\/j.slast.2023.06.005_bib0009","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"issue":"10101","key":"10.1016\/j.slast.2023.06.005_bib0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.slast.2023.06.005_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9020097","article-title":"An update on self-amplifying mRNA vaccine development","volume":"9","author":"Blakney","year":"2021","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.slast.2023.06.005_bib0012","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"de Alwis","year":"2021","journal-title":"Mol Ther"},{"issue":"16","key":"10.1016\/j.slast.2023.06.005_bib0013","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.slast.2023.06.005_bib0014","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.slast.2023.06.005_bib0015","first-page":"85","author":"WHO Expert Committee on Biological Standardization","year":"2020"},{"issue":"1","key":"10.1016\/j.slast.2023.06.005_bib0016","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/22221751.2022.2026742","article-title":"WHO informal consultation on regulatory considerations for evaluation of the quality, safety and efficacy of RNA-based prophylactic vaccines for infectious diseases, 20-22 April 2021","volume":"11","author":"Liu","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.slast.2023.06.005_bib0017","volume":"10","author":"Covarrubias","year":"2022"},{"key":"10.1016\/j.slast.2023.06.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.01.007","article-title":"Characterization of BNT162b2 mRNA to evaluate risk of off-target antigen translation","author":"Patel","year":"2023","journal-title":"J Pharm Sci"},{"issue":"7853","key":"10.1016\/j.slast.2023.06.005_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.slast.2023.06.005_bib0020","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.ymthe.2022.02.001","article-title":"Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine","volume":"30","author":"Muramatsu","year":"2022","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.slast.2023.06.005_bib0021","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcyt.2021.08.005","article-title":"Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials","volume":"24","author":"Ingels","year":"2022","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.slast.2023.06.005_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2202278","article-title":"Development of an mRNA vaccine against a panel of heterologous H1N1 seasonal influenza viruses using a consensus hemagglutinin sequence","volume":"12","author":"Ma","year":"2023","journal-title":"Emerg Microbes Infect"}],"container-title":["SLAS Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472630323000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2472630323000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:10:26Z","timestamp":1762863026000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2472630323000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2472630323000432"],"URL":"https:\/\/doi.org\/10.1016\/j.slast.2023.06.005","relation":{},"ISSN":["2472-6303"],"issn-type":[{"value":"2472-6303","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capillary electrophoresis methods for determining the IVT mRNA critical quality attributes of size and purity","name":"articletitle","label":"Article Title"},{"value":"SLAS Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.slast.2023.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc. on behalf of Society for Laboratory Automation and Screening.","name":"copyright","label":"Copyright"}]}}